Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Vilon cycle length: what human studies ran

Not approved — research use onlyCPreclinical research
Short answer: there is no established Vilon cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Vilon combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Vilon cycle length?
No. We found no human studies that report a treatment duration for Vilon.
What is the longest human study of Vilon?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Vilon dosing reference Full research page

References

  1. Effect of vilon on biological age and lifespan in mice Bull Exp Biol Med. 2000
  2. The effect of vilon (Lys-Glu) on 1.2-dimethylhydrazine-induced neoplasia Vopr Onkol. 2005
  3. Short Exogenous Peptides Regulate Expression of CLE, KNOX1, and GRF Family Genes in Nicotiana tabacum Biochemistry (Mosc). 2017
  4. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line Int J Mol Sci. 2022
  5. Effect of short peptides on expression of signaling molecules in organotypic pineal cell culture Bull Exp Biol Med. 2011
  6. Effects of short peptides on lymphocyte chromatin in senile subjects Bull Exp Biol Med. 2004
  7. Drugs@FDA: FDA-Approved Drugs (search of approved applications) FDA Drugs@FDA / openFDA drug/drugsfda. 2026
  8. DailyMed label search (structured product labels) NLM DailyMed. 2026
  9. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act, updated May 14, 2026 FDA. 2026
  10. World Anti-Doping Code International Standard: Prohibited List 2026 WADA. 2026
  11. [Application of peptide bioregulator in complex treatment of elderly cancer patients] Adv Gerontol. 2005